Clinical Trials Directory

Trials / Completed

CompletedNCT03665506

Trifluridin/tipirACil in MeTastatIc Colorectal Cancer

A Non-interventional Study to Assess Effectiveness and Safety of Trifluridin/tipiracil in Patients with Metastatic Colorectal Cancer

Status
Completed
Phase
Study type
Observational
Enrollment
315 (actual)
Sponsor
Servier · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

A non-interventional, prospective, open, multicenter study in Germany in patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies and with decision for treatment with trifluridin/tipiracil.

Detailed description

The purpose of this NIS, after market approval of trifluridin/tipiracil as treatment for mCRC patients who have been previously treated with, or are not considered candidates for, available therapies, is to evaluate effectiveness, QoL, treatment details and safety of trifluridin/tipiracil treatment in a real-world setting. In addition, therapy management and health economic parameters regarding trifluridin/tipiracil treatment will be assessed.

Conditions

Interventions

TypeNameDescription
DRUGTrifluridin/TipiracilQoL assessment

Timeline

Start date
2018-06-25
Primary completion
2021-08-02
Completion
2021-08-02
First posted
2018-09-11
Last updated
2024-12-03

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT03665506. Inclusion in this directory is not an endorsement.

Trifluridin/tipirACil in MeTastatIc Colorectal Cancer (NCT03665506) · Clinical Trials Directory